重组人干扰素α-2a联合保妇康栓治疗宫颈高危型HPV感染的疗效观察  

Therapeutic Effect of Recombinant Human Interferonα-2a Combined with Baofukang Suppository on High Risk Cervical HPV Infection

作　　者：耿彩彩 GONG Cai-cai(Department of Obstetrics and Gynecology,Nanyang High Tech Zone Hospital Nanyang City,Nanyang Henan 473000,China)

机构地区：[1]南阳市高新区医院妇产科,河南南阳473000

出　　处：《药品评价》2020年第8期27-29,共3页Drug Evaluation

摘　　要：目的:探讨重组人干扰素α-2a联合保妇康栓治疗宫颈高危型人乳头瘤病毒(HPV)感染的疗效。方法:选取2018年1月—2019年4月在我院治疗的78宫颈高危型HPV感染患者,随机分为2组,各39例。对照组给予重组人干扰素α-2a治疗,观察组给予重组人干扰素α-2a+保妇康栓治疗。治疗后,比较两组临床疗效、HPV转阴率、不良反应发生率。结果:治疗后,观察组临床总有效率、HPV转阴率均高于对照组,差异均具有统计学意义(P<0.05);治疗期间,两组不良反应发生率对比,差异不显著(P>0.05)。结论:重组人干扰素α-2a联合保妇康栓治疗宫颈高危型HPV感染可提高HPV转阴率,提高临床疗效,且安全性较高。Objective:To investigate the efficacy of recombinant human interferonα-2a combined with Baofukang suppository in the treatment of cervical high risk human papillomavirus(HPV)infection.Methods:78 patients with cervical high risk HPV infection who were treated in our hospital from January 2018 to April 2019 were randomly divided into two groups,39 cases in each group.The control group was treated with recombinant human interferonα-2a,and the observation group was treated with recombinant human interferonα-2a+Baofukang suppository.After treatment,the clinical efficacy,the negative rate of HPV and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the total clinical effective rate and the negative rate of HPV in the observation group were higher than those in the control group,the difference was statistically significant(P<0.05);during the treatment,the incidence of adverse reactions in the two groups was not significant(P>0.05).Conclusion:The combination of recombinant human interferonα-2a and Baofukang suppository can improve the negative rate of HPV,improve the clinical efficacy and safety.

关 键 词：人乳头瘤病毒感染 宫颈高危型 重组人干扰素Α-2A 保妇康栓 HPV转阴率 不良反应发生率 

分 类 号：R711.32[医药卫生—妇产科学]